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SUMMARY 
Hox-like homeodomain proteins play a critical role during embryonic development by regulating 
the transcription of genes that are important for the generation of specific organs or cell types. 
The homeodomain transcription factor IDX1/IPF1, whose expression was thought until recently 
to be restricted to the pancreas and foregut, is required for pancreas development and for the 
expression of genes controlling glucose homeostasis. We report that IDX1/IPF1 is also expressed 
in embryonic rat brain at a time coincident with active neurogenesis. Electrophoretic mobility 
shift assays with nuclear extracts of embryonic brains indicated that IDX1/IPF1 binds to two 
somatostatin promoter elements, SMS-UE-B and the recently discovered SMS-TAAT3. The 
requirement of these elements for IDX1/IPF1 transactivation of the somatostatin gene in neural 
cells was confirmed in transfection studies using embryonic cerebral cortex-derived RC2.E10 
cells. Immunohistochemical staining of rat embryos showed IDX1/IPF1-positive cells located 
near the ventricular surface in germinative areas of the developing central nervous system. 
Cellular colocalization of IDX1/IPF1 and somatostatin was found in several areas of the 
developing brain, including cortex, ganglionic eminence, hypothalamus and inferior colliculus. 
These results support the notion that IDX1/IPF1 regulates gene expression during development 
of the central nervous system independently of its role on pancreas development and function. 
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INTRODUCTION 
 Homeodomain genes encode a large family of transcription factors that are grouped in 
diferent classes, including, for example, Hox-, POU-, Pax-, LIM-, and Dlx-like proteins, 
depending on the relative degree of conservation of the homeodomain. During gestation, 
expression of individual homeodomain genes is critical for proper regional development of the 
central nervous system (CNS) and peripheral tissues of the embryo. 
 IDX1/IPF1 (also known as STF-1 and PDX-1) is a transcription factor encoded by a Hox-
like homeodomain gene whose expression was initially described to be restricted to the pancreas 
and duodenum, and it has been demonstrated that pancreas development requires IDX1/IPF1 in 
mice (1, 2). This requirement was confirmed in the human by the identification of an individual 
with pancreatic agenesis and a homozygous mutation in the IPF-1 gene (3). In addition, 
IDX1/IPF1 is essential for normal pancreatic islet function by regulating the expression of a 
number of pancreatic genes, including insulin, somatostatin, islet amyloid polypeptide and 
glucose transporter type 2 (4-8). Importantly, in humans, heterozygous mutations of the IPF-1 
gene are linked to a type of autosomal dominant diabetes mellitus known as maturity onset 
diabetes of the young (MODY4) (9). 
 In the developing neural tube, different homeodomain genes that control mechanisms of 
regional and cellular determination are selectively expressed in the primordia of the three major 
regions of the CNS: forebrain, midbrain and hindbrain (10). In the hindbrain, certain Hox-like 
homeodomain genes specify positional information utilized by neural precursor cells to develop 
into appropriate types of neurons or glial cells (11). A similar type of code involving LIM- and 
Pax-homeodomain genes operates in the spinal cord (12). In the midbrain, proper development 
requires the expression of engrailed genes (13, 14). 
 In the forebrain, expression of most Hox genes is not readily detectable. However, other 
classes of mammalian homeobox genes, including Nkx, Otx, Emx and Dlx, show restricted 
patterns of expression preferentially located in the forebrain (15), and are required for the 
development of forebrain structures  (16-18) or for the differentiation of specific cell types in 
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different regions of the brain (18, 19). In addition, homeodomain transcription factors of two 
other classes (POU and Pax) are important for forebrain development (20-23). 
 In a preliminary study, we found that expression of IDX1/IPF1 during embryonic 
development occurs in the CNS as well as in the pancreas (24). In the present study, we provide 
evidence that the somatostatin gene is a target for regulation by IDX1/IPF1 in neural cells, and 
that neural expresion of IDX1/IPF1 is spacially and temporally regulated during CNS 
development. Thus, our data reinforce the notion that the transcriptional functions of IDX1/IPF1 
are broader than previously anticipated, as they indicate the likelihood that IDX1/IPF1 plays a 
role in neural development. 
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EXPERIMENTAL PROCEDURES 
RT-PCR/Southern blot hybridization analyses. Developing brains from rat embryos removed at 
different gestation times from timed-pregnant Sprague-Dawley rats were dissected under the 
microscope and the meningeal membranes were carefully removed. Brains of E16 and E19 
embryos were further dissected into two parts by a transverse section made at the level of the 
caudal edge of the cerebral cortex. The piece rostral to this cut was labeled as forebrain, and the 
piece caudal to this cut was labeled as hindbrain. In addition, brains were removed from adult 
rats and several brain regions were dissected as described (25). Total RNA (10 µg) from 
individual samples was incubated with poly-(dT)15 and avian myeloblastosis virus reverse 
transcriptase to synthesize cDNA.  
 For PCR amplification of IDX1/IPF1, two different sets of primers were used in 
independent experiments, yielding identical results. In the first set, a forward primer that 
corresponds to nucleotides 90 to 117 (5'-CGGCTGCAACCATGGATAGTGAGGAGCAG-3'), 
and a reverse primer that anneals to nucleotides 280 to 296 (5'-AAGTCCCCCGGACATCT-3') 
of the published cDNA (6) were used. In the second set, a forward primer that corresponds to 
nucleotides 96 to 118 (5'-CCACCATGAATAGTGAGGAGCA-3'), and a reverse primer that 
anneals to nucleotides 305 to 322 (5'-GGCGAGCGGGGGCACTTC-3') were used. In both cases 
PCR conditions were: 98 °C for 1 min, followed by 30 cycles of 96° C for 30 sec, 56° C for 30 
sec, and 75° C for 1 min, after which a 5 min incubation at 75° C followed. After PCR, an 
aliquot of the reaction was resolved in a 1% agarose gel, blotted onto a nylon membrane, probed 
with a 32P-labeled internal primer that anneals to nucleotides 216 to 236 (5'-
GCCGCCAGCCCCCACCTCCGC-3'), and autoradiographed at -70° C. 
 Primers for PCR amplification of Emx-1 and Dlx-2 were designed based on the published 
sequences of the rat cDNAs (26). Emx-1 forward primer (nucleotides 10 to 31): 5'-
CCTGGCTGGCTGGGTGCACACC-3'; reverse primer (nucleotides 278 to 289): 5'-
CCACTCACGAAGGCCGCCTCG-3'. PCR conditions were: 94 °C for 5 min, followed by 30 
cycles of 96° C for 30 sec, 65° C for 30 sec, and 75° C for 1 min, after which a 5 min incubation 
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at 75° C followed. As a probe to detect the PCR product after blotting onto nylon, the following 
32P-labeled internal primer was used: 5'-CACTCCTCTTCGGCGGCAGCG-3'. Dlx-2 forward 
primer (nucleotides 1 to 23): 5'-ACAGCCATGTCTGCTTAGACCAG-3'; reverse primer 
(nucleotides 298 to 321): 5'-TTCACGCCGTGATACTGATACTGG-3'. PCR conditions were: 
98 °C for 1 min, followed by 30 cycles of 96° C for 30 sec, 60° C for 30 sec, and 75° C for 1 
min, after which a 5 min incubation at 75° C followed. The 32P-labeled internal primer used as a 
probe to detect the PCR product was 5'-ACTTCCAAGCTCCGTTCCCGA-3'. 
 For PCR amplification of actin, the primers used were as follows: Forward, 5'-
GACGATATGGAGAAGATTTGGCA-3', which anneals to exon 2; Reverse, 5'-
CCATCTCTTGCTCGAAGTCTAGG-3', which anneals to exon 3. The following protocol was 
used: 94°C for 5 min, followed by 20 cycles of 95°C for 30 sec, 50°C for 30 sec, and 72°C for 30 
sec, after which a 5 min incubation at 72°C followed. As a probe to detect the PCR product after 
blotting onto nitrocellulose, the following 32P-labeled internal primer was used: 5'-
CACACGCAGCTCATTGTAGAAAGT-3'. 
 In all cases, controls were carried out in which samples were treated with RNase A prior 
to cDNA synthesis to rule out genomic DNA contamination. In preliminary experiments, 
different numbers of PCR cycles were tested to ensure that the resulting signal in most samples 
does not increase to saturation.  
 
Western immunoblots. Brain samples or cell lines were lysed in buffer containing 125 mM Tris-
HCl (pH 6.8), 4% SDS, 15% glycerol, 10% β-mercaptoethanol, and 10 mM dithiothreitol. 
Proteins were resolved by SDS-PAGE and blotted onto a nitrocellulose membrane. 
Immunoreactivity was detected with the α253 antiserum (1:10,000 dilution) (3, 27), and 
visualized by enhanced chemiluminescence (ECL, Amersham, Buckinghamshire, England). 
 
DNA-Protein binding assays. Electrophoretic mobility shift assays (EMSA) were carried out 
with nuclear extracts of rat developing forebrains or RC2.E10 cells exactly as described (28). For 
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competitions, wild type, mutated TAAT oligonucleotides (6, 28), or non-specific 
oligonucleotides of unrelated sequences were used. The sequences of all the oligonucleotides 
used have been published previously (6, 28-30). 
  
Cell lines and transfections. Neural RC2.E10 cells derived from rat E16 embryonic cortex (28), 
and rat pancreatic islet somatostatin-producing RIN-1027-B2 cells (31) were used and cultured 
as described. All plasmids and transient transfections of RC2.E10 cells using Lipofectin (Gibco 
Laboratories, Grand Island, N.Y.) have been described (6, 28). 
 
Immunohistochemistry. Rat fetuses of different ages were removed from timed-pregnant 
Sprague-Dawley rats and fixed overnight in 4% paraformaldehyde. After fixation, they were 
washed with phosphate-buffered saline (PBS), transferred to PBS containing 20% sucrose, and 
kept at 4°C for at least 24 hours. Sagittal cryostat sections (10 µm) were cut and kept at -80°C 
until used. Sections were brought to room temperature, permeabilized with methanol for 2 min at 
-20° C, treated with 5% normal goat serum and then incubated overnight with the α253 anti-
IDX1/IPF1 antiserum (1:1500 dilution) at 37°C. Immunodetection was carried out with a 
secondary biotinylated goat antirabbit antiserum (Bio-Rad Laboratories, Hercules, CA) using 
nickel-intensified immunoperoxidase staining with a Vectastain ABC kit (Vector Laboratories, 
Burlingame, CA).  
 Two-color dual antigen immunostaining was carried out serially as described (32). First, 
somatostatin was detected with a specific monoclonal rat antiserum (33) diluted 1:100, using 
immunoperoxidase staining enhanced with nickel ammonium, which yields a dark blue color. 
Sections were then washed, and IDX1/IPF1 immunohistochemistry proceeded as described 
above, using immunoperoxidase staining without nickel ammonium, yielding a brown color. 
 
Degenerate RT-PCR. Three regions of the rat brain, cortex, hippocampus and 
hypothalamus/thalamus, were dissected essentially as described (34, 25), with the exception that 
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only parietal cortex was taken, and that the hypothalamus/thalamus was dissected as a single 
block of tissue. Total RNA (10 µg) purified by CsCl gradient centrifugation from each one of 
these regions was primed with poly-(dT)15 and incubated with avian myeloblastosis virus reverse 
transcriptase (Boehringer Mannheim Biochemicals, Indianapolis, IN) to synthesize cDNA. One 
tenth of this cDNA preparation was used for PCR, using degenerate oligonucleotides 
corresponding to conserved residues found in helices 1 and 3 of Hox-like homeodomains. A 
control sample that lacked RNA was processed in parallel. The resulting PCR products were 
ligated into pBluescript (KS) (Stratagene, La Jolla, CA), and after transforming E. coli JM109, 
25-30 individual colonies corresponding to each brain region were randomly picked, and plasmid 
minipreps were prepared and sequenced using the dideoxy chain termination method (Sequenase 
kit; US Biochemicals, Cleveland, OH). Degenerate oligonucleotide sequences, PCR conditions 
and subcloning procedure were exactly as described (6, 35). Sequences were compared with 
GenBank database by using the BLAST Network Service provided by the National Center for 
Biotechnology Information. 
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RESULTS 
Expression of IDX1/IPF1 in the developing CNS 
 To confirm that IDX1/IPF1 is expressed in the brain we carried out RT-PCR/Southern 
blot hybridization analysis with specific primers to IDX1/IPF1, using embryonic as well as adult 
rat brains. As a control to monitor developmental changes in homeodomain gene expression, we 
determined, in parallel experiments using the same template for RT-PCR reactions, the 
expression of Emx-1 and Dlx-2, two homeodomain genes known to be expressed restrictively in 
telencephalic areas of the developing brain (18, 19, 36-38). As expected, Emx-1 and Dlx-2 
transcripts were present in the brains of embryonic day 14 (E14) and E15 rats, enriched in the 
forebrain relative to the hindbrain (Fig. 1, E16 and E19). We found that IDX1/IPF1 transcripts 
are present in the brains of E14 and E15 rats (Fig. 1). In contrast to Emx-1 and Dlx-2, there was 
no difference in the levels of expression of IDX1/IPF1 between forebrain and hindbrain at E16. 
Finally, at E19, expression of Emx-1 and Dlx-2 was robust and restricted to the forebrain, but 
IDX1/IPF1 levels had decreased both in the forebrain and in the hindbrain (Fig. 1). 
 In the adult brain, IDX1/IPF1 transcripts appeared to be of relatively low abundance in 
most regions examined, with the exception of the cerebellum (Fig. 1). As expected, Emx-1 and 
Dlx-2 were found preferentially expressed in telencephalic areas (hippocampus, striatum and 
cortex) (Fig. 1). 
 Immunochemical detection of IDX1/IPF1 protein in neural cells was carried out initially 
by Western immunoblotting using an antiserum (α253) that recognizes specifically the C-
terminal 12 amino acids of IDX1/IPF1 (3, 27). Western immunoblot analysis confirmed that this 
antiserum recognizes both IDX1/IPF1 synthesized in vitro, and IDX1/IPF1 constitutively 
expressed in pancreatic islet-derived RIN-1027-B2 cells (Fig. 2), a cell line from which 
IDX1/IPF1 was originally cloned (6). In addition, we detected immunoreactive IDX1/IPF1 in 
nuclear extracts of E15 and E17 rat brains, as well as in nuclear extracts of RC2.E10 cells (Fig. 
2), a neural precursor cell line derived from rat embryonic cortex (28, 73). 
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 The finding of IDX1/IPF1 in RC2.E10 cells, which express the somatostatin gene in a 
neural-specific manner (28), prompted us to explore the possibility that IDX1/IPF1 regulates 
somatostatin gene expression in neural cells. 
 
IDX1/IPF1 present in neural cells binds to somatostatin gene DNA-regulatory elements 
 The promoter region of the somatostatin gene contains at least four homeodomain-
binding DNA regulatory elements with a common TAAT core motif, named SMS-UE-B, SMS-
TAAT1, SMS-TAAT2, and SMS-TAAT3, some of which appear to act as targets for regulation 
of somatostatin gene expression by IDX1/IPF1 in pancreatic cells (5, 6, 28, 30, 39). We sought 
to investigate whether IDX1/IPF1 expressed in developing neural tissue is able to bind to these 
elements. 
 Initially, we determined by EMSA that nuclear extracts prepared from embryonic rat 
brains contain proteins that recognize synthetic oligonucleotides corresponding to these TAAT 
sites. Several specific DNA-protein complexes, distributed in three different clusters of slow 
(cluster 1), medium (cluster 2) and fast (cluster 3) relative electrophoretic mobility, were found 
to bind to SMS-TAAT1 (Fig. 3A). No appreciable differences were observed between brain 
nuclear extracts prepared from E14 or E16 embryos (Fig. 3A). A similar pattern was found when 
the SMS-TAAT2 probe was used, with the exception that the bands corresponding to complex 1 
were not detected (Fig. 3B). 
 When the SMS-TAAT3 probe was used, only two major protein-DNA complexes with 
relatively slow electrophoretic migration were detected in brain nuclear extracts from E14 or E16 
embryos (Fig. 3C). Finally, two complexes were found to bind to SMS-UE-B in brain nuclear 
extracts from E14 embryos, but only one was detected when brain nuclear extracts were prepared 
from E16 embryos (Fig. 3D). 
 To investigate whether any of the complexes observed with embryonic brain nuclear 
extracts contain IDX1/IPF1, we carried out EMSA in the presence of the α253 antiserum, or in 
the presence of a different anti-IDX1/IPF1 antiserum (α251) which specifically recognizes the 
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N-terminal 12 amino acids of IDX1/IPF1 (3, 27). The addition of either of these antisera to the 
binding reaction did not disturb the protein complexes bound to SMS-TAAT1 and SMS-TAAT2 
(not shown). However, we found that the presence of either of these antisera in the binding 
reaction results in the disappearance of the upper band detected with the SMS-TAAT3 (Fig. 4A) 
or with the SMS-UE-B probes (Fig. 4B). Similar results were obtained when nuclear extracts 
from neural RC2.E10 cells, which express the somatostatin gene (28), where used (not shown). 
Thus, these experiments identify IDX1/IPF1 as a homeodomain transcription factor that binds 
somatostatin gene regulatory elements in neural cells. 
 
IDX1/IPF1 activates somatostatin gene expression in neural cells 
 We carried out transient transfection experiments to evaluate the transactivational activity 
of IDX1/IPF1 on the somatostatin gene. First, we confirmed that transfection of RC2.E10 cells 
with pBJ5-IDX-1 (6), an expression plasmid encoding IDX1/IPF1, results in elevated levels of 
IDX1/IPF1 expression (Fig. 5A). We then cotransfected increasing amounts of the pBJ5-IDX-1 
plasmid with a fixed amount of plasmid SMS900, a chloramphenicol acetyl transferase (CAT) 
reporter plasmid which contains a fragment of the somatostatin gene spanning nucleotides -900 
to +54 (40). Expression of SMS900 after transient transfections in RC2.E10 cells has previously 
been characterized (28). Cotransfection of pBJ5-IDX-1 and SMS900 resulted in a concentration-
dependent increase in the levels of CAT activity (Fig. 5C). 
 To determine whether any of the TAAT-containing elements of the somatostatin gene 
promoter are important for IDX1/IPF1 transactivation in neural cells, we carried out another 
series of transient cotransfection experiments in RC2.E10 cells, using mutant SMS900 plasmids 
in which each one of the TAAT motifs had been altered by site-directed mutagenesis in such a 
way that binding of nuclear proteins is impaired (28). 
 Disruption of either SMS-TAAT1 or SMS-TAAT2 (Fig 5D), or of both elements together 
(not shown), did not alter the transactivation activity of IDX1/IPF1. However, disruption of 
either SMS-TAAT3 or SMS-UE-B independently, inhibited the increase in the levels of CAT 
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activity elicited by cotransfection with pBJ5-IDX-1 (Fig. 5D), indicating that the integrity of 
these elements is required for the transactivation of the somatostatin gene by IDX1/IPF1 in 
neural cells. 
 
Distribution of IDX1/IPF1-expressing cells in the developing brain 
 To gain information on the regional distribution of cells expressing IDX1/IPF1 in the 
developing CNS, we carried out immunohistochemistry on sagittal sections of rat embryos. As 
expected, we observed IDX1/IPF1 immunoreactivity in the duodenum and pancreatic 
mesenchyme (not shown). In the developing CNS, we found IDX1/IPF1 expressed in several 
regions.  
 In the telencephalon, cells with IDX1/IPF1 immunopositive nuclei were readily 
detectable throughout the depth of the neocortical neuroepithelium of E14 and E15 embryos 
(Fig. 6A). At E15, a higher density of cells was often found clustering in the subventricular zone 
(Fig. 6A). The intensity of immunostaining and relative number of immunopositive cells 
decreased at E16. In the neocortical epithelium of these embryos, IDX1/IPF1-positive cells were 
restricted to the ventricular and subventricular zones, and by E17 IDX1/IPF1 immunoreactivity 
in the neocortex was practically undetectable (Fig. 6A), and positive nuclei were observed only 
occasionally. IDX1/IPF1 was also found expressed in the archicortex, which corresponds to the 
hippocampal primordium (Fig. 6B), as well as in the germinative layers of the medial and lateral 
ganglionic eminence corresponding to the striato-pallidal primordium that generates the basal 
ganglia (Fig. 6B). However, at E17 IDX1/IPF1 expression in the hippocampus and basal ganglia 
was undetectable (not shown).  
 IDX1/IPF1 immunoreactivity was also found in periventricular areas of the hypothalamus 
of E14 and E15 embryos, in scattered cells surrounding the optic, mammillary and infundibular 
recesses (not shown), as well as in the anterior hypothalamic neuroepithelium and the tuberal 
hypothalamus, where the highest density of cells with immunopositive nuclei was observed (Fig. 
6B). No IDX1/IPF1 immunoreactivity was detected in the hypothalamus of E17 embryos. 
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 In the mesencephalon, IDX1/IPF1 immunopositive cells were found in the pretectum and 
in the tectum, as well as in the tegmental neuroepithelium (Fig. 6B). In rostral areas (pretectum 
and superior colliculus), expression decreased as development proceeded, so that in E17 embryos 
a relatively smaller number of positive cells were detected. In contrast, IDX1/IPF1 
immunoreactivity in the caudal mesencephalon did not decrease, and many immunopositive cells 
were detected in the inferior colliculus of E17 embryos (Fig. 6C). 
 More caudally, expression of IDX1/IPF1 was found in the cerebellar primordium of E14 
(not shown) and E15 embryos, in cells that were located close to the ventricular surface (Fig. 
6B). No immunoreactivity was detected in E17 embryos. 
 Finally, intensely immunoreactive cells restricted to the area postrema appeared late in 
development (Fig. 6C). Also, in E17 embryos immunopositive cells were detected in the 
developing pineal gland (Fig. 6C). 
 
Coexpression of IDX1/IPF1 and somatostatin in neural cells 
 In pancreatic cells, IDX1/IPF1 regulates somatostatin gene expression (5, 6, 39). In the 
CNS, somatostatin expression first appears at E14, and its developmental pattern of expression 
coincides with the spatial and temporal pattern that we found for IDX1/IPF1 (41-43). Therefore, 
we sought to determine whether somatostatin and IDX1/IPF1 are coexpressed in the same cells 
in the CNS during embryonic development. The presence of somatostatin-immunoreactive cells 
in different brain regions of E15 embryos, including ganglionic eminence, cortex (Fig. 7), 
hypothalamus and mesencephalon (not shown), was confirmed a priori by standard 
immunohistochemistry. Dual antigen immunohistochemistry revealed the presence of 
immunopositive cells for both somatostatin and IDX1/IPF1 in these areas (Fig. 7). The vast 
majority of somatostatin-positive cells stained positively for IDX1/IPF1, strongly supporting the 
notion that IDX1/IPF1 may also regulate somatostatin gene expression in neural cells. In 
addition, we detected a number of cells that showed IDX1/IPF1-positive nuclei, but did not stain 
for somatostatin (Fig. 7). 
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Expression of Hox-like genes in brain tissue 
 To further investigate the expression of IDX1/IPF1 and other Hox genes in the forebrain, 
we carried out RT-PCR using RNA purified from three different adult brain regions. As PCR 
primers, we used degenerate oligonucleotides encoding the sequences ELEKE and KIWFQN, 
conserved in the homeodomains of Hox-like proteins. Sequence analyses of individual clones 
prepared from the resulting PCR products revealed the presence of several Hox-like genes 
expressed in each of the different brain regions analyzed (Table 1). 
 In the hypothalamus/thalamus region, 52% of the clones sequenced encode the 
homeodomain of Gbx-2, also known as MMox-A (44), and 12% of the clones encode MAB26. 
Both of these Hox-like homeodomain sequences had been previously found expressed in 
developing mouse telencephalon using different degenerate primers (44). In addition, Gbx-2 has 
been shown to be expressed in the diencephalic area that contains the prospective dorsal 
thalamus in mouse embryos (36, 45). MAB26 was the most frequently found clone in the 
hippocampus, followed by HoxA1 (Table 1). HoxA1 was also found with relatively high 
frequency (28%) in the cortex. However, in this region the most frequently found sequence 
(34%) encoded the homeodomain of IDX1/IPF1. 
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DISCUSSION 
 Although expression of the homeodomain transcription factor IDX1/IPF1 has been 
described to be restricted to the foregut and pancreas, we reported recently evidence indicating 
its expression also in the developing CNS (24). This study demonstrates that expression of 
IDX1/IPF1 in neural cells is developmentally regulated in a region- and time-specific manner. In 
the cortex, ganglionic eminence and hypothalamus, expression decreases as development 
proceeds, whereas in other areas such as the inferior colliculus and area postrema, expression 
progressively increases or appears later in development, respectively. This dual mode of 
expression is reminiscent of the pattern of IDX1/IPF1 expression in the pancreas. At early stages, 
it occurs in proliferative cells of the growing pancreatic primordium in both exocrine and 
endocrine compartments (1, 2), but subsequently it is restricted to cells in the islets of 
Langerhans, consistent with two independent functions, one related to the genesis of insulin-
producing β-cells, and the other related to the maintenance of their phenotype and of glucose 
homeostasis (46, 47). 
 Our data supports that IDX1/IPF1 participates in the regulation of the neural-specific 
expression of the somatostatin gene. In pancreatic δ-cells, IDX1/IPF1 regulates somatostatin 
gene expression by binding SMS-UE-B (also known as TSE-I) and SMS-TAAT1 (also known as 
TSE-II) (5, 6, 39, 48, 49). However, in neural cells, SMS-TAAT1 (or SMS-TAAT2) does not 
appear to be recognized by IDX1/IPF1. A comparison of the effects of both α251 and α253 
antisera on the binding of nuclear proteins from neural RC2.E10 cells and from somatostatin-
producing pancreatic RIN-1027-B2 cells confirmed that, even though IDX1/IPF1 is present in 
both cell types, it binds to SMS-TAAT1 and SMS-TAAT2 only in pancreatic cells (not shown), 
suggesting that differences in the protein environment within the nucleus of neural or pancreatic 
cells can alter IDX1/IPF1 DNA binding specificity. Indeed, the requirement of the integrity of 
the SMS-UE-B and SMS-TAAT3 elements suggests that the protein complexes bound to each 
one of them may engage in interactions that are functionally important for IDX1/IPF1 
transactivation in neural cells, as it occurs in pancreatic cells (39, 48-52). 
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 In the embryo, the location of IDX1/IPF1-expressing cells close to the ventricular surface 
in areas of the developing CNS such as hypothalamus, ganglionic eminence and cortex, suggests 
that those cells are proliferative or differentiating neural precursors. In the hypothalamus, 
IDX1/IPF1 is present at a time of active neurogenesis (reviewed in ref. 20) in regions that 
generate neurons for several nuclei, including those with the highest number of somatostatin-
expressing cells (periventricular, suprachiasmatic, and arcuate nuclei, and anterolateral 
hypothalamus) (43, 53). 
 Expression of IDX1/IPF1 in cells of the germinative zone of the ganglionic eminence 
coincides with a peak of neurogenesis in this structure (54-57). It has been suggested that other 
homeodomain proteins of different families (POU, Lhx, and Dlx), also expressed in the 
germinative zone at this time, participate in the initiation of the differentiation program of 
proliferating precursors (18, 20, 22, 58). Thus, IDX1/IPF1 could act coordinately with some of 
these transcription factors to generate combinatorial codes for the selective regulation of specific 
genes. Interestingly, striatal somatostatin-expressing interneurons are generated at this time (56, 
57).  
 In the cortex, IDX1/IPF1 was found in cells of the proliferating neuroepithelium, often 
close to the ventricular surface (E14 and E15), but not in layers distal to the intermediate zone 
(E16). Thus, IDX1/IPF1 appears to be down-regulated as differentiating precursors or young 
neurons migrate through the cortex. In the rat, cortical neurogenesis takes place up until E20 (20, 
59), but expression of IDX1/IPF1 was practically undetectable by E17. Therefore, the observed 
pattern of IDX1/IPF1 expression in the developing cortex is consistent with a role in neural 
precursors that generate specific types of neurons during a restricted period of time, but not in 
the maintenance of their mature phenotype. One of these types may correspond to somatostatin-
producing neurons. Like IDX1/IPF1, somatostatin gene expression in many cells of the 
developing brain is transient, so that the relative number of somatostatin-expressing cells in the 
mature cortex is lower than that present during corticogenesis (41, 43, 60, 61). 
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 We found a number of cells that stain for IDX1/IPF1 but not for somatostatin in all areas 
examined. Thus, IDX1/IPF1 probably regulates the expression of other genes in the CNS, but 
their identities are unknown. Nonetheless, that the somatostatin gene is a target for regulation by 
IDX1/IPF1 in neural cells is further supported by our EMSA and transfection studies using 
somatostatin-expressing cortex-derived RC2.E10 cells.  
 One function of IDX1/IPF1 is to participate in the homeostatic control of normoglycemia 
by coordinately regulating the expression of several genes involved in glucose-sensing 
mechanisms and glucose utilization in the pancreas (46, 47). The brain acts as a center for the 
integration of information pertaining to fuel metabolism and energy homeostasis (62). In 
particular, the area postrema contains glucose-responsive neurons, and the hypothalamus 
contains glucose-, glucagon-like peptide-1-, and leptin-responsive neurons, that may play a role 
in the central control of food intake and maintenance of normoglycemia (63-66). Our finding of 
IDX1/IPF1 in the developing hypothalamus and area postrema, suggests that one putative 
function of IDX1/IPF1 in the embryo may be the development of an integrated system of cells 
located both in the CNS and in the periphery, to coordinately regulate glucose uptake and 
metabolism. 
 The effects of the inactivation of IDX1/IPF1 on pancreas development have been 
assessed in detail in mutant mice (1, 2, 46, 47), but no studies on the development of the CNS in 
those mice have been reported. IDX1/IPF1 mutant mice exhibit lack of pancreas and early 
postnatal lethality (1, 2), preventing the finding of any possible neural deficit. However, possible 
defects due to lack of IDX1/IPF1 in the CNS may be subtle and not readily apparent unless 
purposely studied in detail, as it is the case for other homeodomain genes (18, 19). 
 Several genes encoding transcription factors, including Nkx2.2, Isl-1, and 
BETA2/NeuroD, are restrictively expressed in both developing pancreas and CNS. Targeted 
disruption of the Isl-1 gene results in early arrest of pancreatic development and embryonic 
lethality (67). Like mice lacking IDX1/IPF1, mice with inactivation of the genes encoding 
BETA2/NeuroD or Nkx2.2 develop severe neonatal diabetes, due to alterations in pancreatic 
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development, and die postnatally (68, 69). In the CNS, lack of BETA2/NeuroD or Nkx2.2 results 
in alterations in the differentiation of specific populations of neural cells (70, 71). Whether 
neural alterations in specific areas of the CNS contribute to the observed early postnatal lethality 
of these mice remains unknown. Thus, the possibility of specific defects in the CNS of 
IDX1/IPF1 mutant mice merits further detailed investigation. 
 The finding of a human subject with a homozygote mutation in IDX1/IPF1 and 
pancreatic agenesis led to the proposal that other genes such as BETA2/NeuroD or Nkx2.2 may 
also be candidates for human neonatal diabetes (69). It is noteworthy that, although this is a rare 
condition, a recent survey of reported cases revealed that a significant proportion of patients (at 
least 20%) exhibit signs of neural defects including impaired mental and motor development 
(72). This observation, together with the findings reported in this study, support the notion that 
some elements of the transcriptional control of neuronal and pancreatic differentiation are 
conserved (67), despite the different ontogenic origins of these tissues. 
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FIGURE LEGENDS 
 
Fig. 1. Expression of IDX1/IPF1 transcripts in embryonic and adult central nervous system as 
assessed by RT-PCR/Southern. For E14 and E15 embryos, the whole brain was used. For E16 
and E19 embryos, the brain was divided into forebrain (F) and hindbrain (H). Expression of 
Emx-1 and Dlx-2, two unrelated homeodomain genes preferentially expressed in the forebrain 
were used for comparison. For each lane, IDX1/IPF1, Emx-1, Dlx-2 and actin were amplified 
using aliquots of the same cDNA template. The bottom panel shows the results of densitometric 
analyses carried out to quantify the relative intensity of IDX1/IPF1 bands. Results of two 
independent experiments are depicted: black bars correspond to the experiment shown on the top 
panel, and white bars correspond to a different experiments (not shown). Results are expressed as 
percentage of increment of densitometry measurements of IDX1/IPF1 bands (in arbitrary units) 
relative to the intensity of the corresponding actin bands. Densitometry of scanned 
autoradiographs was carried out using NIH Image 1.62 software. Abbreviations are: MB, 
midbrain; HYP, hypothalamus; HIPP, hippocampus; STR, striatum; BSTM, brainstem; CER, 
cerebellum; CTX, cortex. 
 
Fig. 2. Detection of IDX1/IPF1 protein by Western immunoblotting using the α253 antiserum. 
Arrow indicates immunoreactive IDX1/IPF1. RL, unprogrammed rabbit reticulocyte lysate; 
IDX-1, IDX1/IPF1 synthesized in rabbit reticulocyte lysate; RIN-B2, extract from pancreatic 
islet RIN-1027-B2 cells; RC2.E10, extract from developing cortex-derived RC2.E10 cells. Brain 
extracts of E15 and E17 rat embryos included only the forebrain. Similar experiments were 
repeated at least three times. 
 
Fig. 3. Electrophoretic mobility shift assays indicating the binding of nuclear proteins prepared 
from E14 or E16 rat brains to SMS-TAAT1 (A), SMS-TAAT2 (B), SMS-TAAT3 (C) and SMS-
UE-B (D). Oligonucleotide probes used in each assay are indicated at the bottom. Clusters of 
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protein complexes with different electrophoretic mobility bound to SMS-TAAT1 and SMS-
TAAT2 are numbered. Nuclear extracts were incubated in the absence (-) or presence of 
competing oligonucleotides (10- or 100-fold molar excess) of identical probe sequence, or in the 
presence of the corresponding mutated TAAT oligonucleotide (Mut) used in a 100-fold molar 
excess. One representative example of at least five independent experiments is shown. 
 
Fig. 4. Electrophoretic mobility shift assays showing the binding of IDX1/IPF1 present in 
nuclear extracts of E14 and E16 rat brains to oligonucleotide probes corresponding to the 
somatostatin SMS-TAAT3 and SMS-UE-B elements. Binding reactions were carried out in the 
presence of either normal rabbit serum (NRS) or anti-IDX1/IPF1 α251 or α253 antisera. Arrows 
indicate bands corresponding to protein-DNA complexes containing IDX1/IPF1. One 
representative example of three independent experiments is shown. 
 
Fig. 5. IDX1/IPF1 transactivates the somatostatin gene promoter in embryonic cerebral cortex-
derived RC2.E10 cells. (A) Western immunoblotting carried out with the anti-IDX1/IPF1 α253 
antiserum demonstrating over-expression of IDX1/IPF1 in RC2.E10 cells transfected with pBJ5-
IDX-1. (B) Schematic representation of wild-type (SMS900) and mutated (M) somatostatin CAT 
reporter plasmids used to transfect RC2.E10 cells. TAAT-containing elements are depicted as 
open boxes, and their mutated versions are indicated as black boxes. The elements are: T1, SMS-
TAAT1; T2, SMS-TAAT2; T3, SMS-TAAT3; and UE, SMS-UE-B. (C) Relative CAT activities 
elicited by SMS900 (15 µg) in the absence (-) or presence of different amounts of pBJ5-IDX-1 
observed after transfections in RC2.E10 cells. (D) Relative CAT activities elicited by each one of 
the somatostatin CAT reporter plasmids depicted in (B) cotransfected in RC2.E10 cells with 2.5 
µg of pBJ5-IDX-1 (IDX-1) or pBJ5 with no insert (Vector). Values for CAT activities are 
expressed as percentages of the activities elicited by wild type SMS900 CAT, and represent the 
mean + s.e.m. of at least three independent experiments carried out in duplicate. 
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Fig. 6. Immunohistochemical localization of IDX1/IPF1-expressing cells in the central nervous 
system of developing rats. Images depict nuclear localization of IDX1/IPF1 in black. All pictures 
correspond to parasagittal sections of developing rat brains, prepared at the indicated gestation 
times (E14 to E17), and are oriented so that anterior is left and dorsal is at the top. (A) 
Decreasing expression in the developing neocortex observed between E14 and E17. At E14, 
IDX1/IPF1 immunopositive cells are present throughout the entire thickness of the 
neuroepithelium; at E15 the highest density of immunoreactive cells are found close to the 
ventricular surface, and at E16 weakly immunoreactive cells occupy the ventricular and 
subventricular zones; IDX1/IPF1 cells were undetectable at E17. (B) IDX1/IPF1 immunopositive 
cells in different brain regions at E15. (C) IDX1/IPF1-immunopositive cells observed at a late 
gestation time (E17) when immunoreactivity in other brain areas is no longer detectable. All 
pictures were taken at the same magnification.  Scale bar represents 50 µm. A total of 14 
immunnohistochemical determinations on eight embryos were carried out by two researchers 
independently. Abbreviations: 3V, third ventricle; 4V, fourth ventricle; acx, archicortex 
(hippocampus); ah, anterior hypothalamic neuroepithelium; ap, area postrema; aq, aqueduct; cb, 
cerebellar primordium; hyp, hypothalamus; ic, inferior colliculus; iz, intermediate zone; lge, 
lateral ganglionic eminence; LV, lateral ventricle; mge, medial ganglionic eminence; pt, 
pretectum; pyr, pyramidal tract; sc, superior colliculus; svz, subventricular zone; teg, tegmental 
neuroepithelium; tu, tuberal hypothalamus; vz, ventricular zone. 
 
Fig. 7. Coexpression of IDX1/IPF1 and somatostatin demonstrated by dual antigen 
immunohistochemistry in parasagittal sections of E15 rat brain. Sections were stained only for 
somatostatin (A and C) of for both somatostatin and IDX1/IPF1 (B and D). Neocortex (A and B) 
and ganglionic eminence (C and D) are shown. Somatostatin immunoreactivity (depicted in blue) 
is localized to the cytoplasm, and IDX1/IPF1 immunoreactivity (depicted in brown) is localized 
to the nucleus. Arrows indicate examples of doubly labeled cells. Arrowheads indicate examples 
of cells that stained for IDX1/IPF1 but not for somatostatin. Scale bar represents 20 µm. LV, 
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lateral ventricle. Coexpression of IDX1/IPF1 and somatostatin was confirmed in four 
independent experiments. 
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TABLE 1. Sequences encoding Hox-like homeodomains detected by cloning and sequencing of 
degenerate RT-PCR products obtained from RNAs expressed in three different brain regions.  
   
Hypothalamus/Thalamus Hippocampus  Cortex  
(25 clones) (30 clones) (29 clones) 
     
GenBank No. of GenBank No. of GenBank No. of 
match clones match clones match clones 
 
       
Gbx-2 13 (52%) MAB26 10 (33%) IDX1/IPF1 10 (34%) 
MAB26 3 (12%) HoxA1 5 (17%) HoxA1 8 (28%) 
HoxA9 2 (8%) HoxB1 4 (13%) HoxB9 3 (10%) 
HoxA4 1 (4%) HoxC8 4 (13%) HoxC9 2 (7%) 
HoxB1 1 (4%) HoxD9 3 (10%) HoxA4 1 (3%) 
HoxB6 1 (4%) HoxC4 2 (6%) HoxA7 1 (3%) 
HoxB9 1 (4%) HoxA3 1 (3%) HoxD4 1 (3%) 
HoxC5 1 (4%) No match 1 (3%) Cdx-2/3 1 (3%) 
HoxC9 1 (4%)   No match 2 (7%) 
No match 1 (4%)     
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